Glatiramer acetate attenuates the pro‐migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis
Johann Sellner,W. Koczi,Andrea Harrer,Katrin Oppermann,E. Obregon-Castrillo,Georg Pilz,Peter Wipfler,Shahrzad Afazel,Elisabeth Haschke-Becher,Eugen Trinka,Jörg Kraus +10 more
Reads0
Chats0
TLDR
The deregulated pro‐migratory expression profile of cell‐bound AM is altered by GA treatment, and protracted development and unselective changes indicate more secondary immune regulatory phenomena related to these effects.Abstract:
An altered expression pattern of adhesion molecules (AM) on the surface of immune cells is a premise for their extravasation into the central nervous system (CNS) and the formation of acute brain lesions in multiple sclerosis (MS). We evaluated the impact of glatiramer acetate (GA) on cell-bound and soluble AM in the peripheral blood of patients with relapsing-remitting MS (RRMS). Fifteen patients treated de novo with GA were studied on four occasions over a period of 12 months. Surface levels of intracellular cell adhesion molecule (ICAM)-1, ICAM-3, lymphocyte function-associated antigen (LFA)-1 and very late activation antigen (VLA)-4 were assessed in T cells (CD3(+) CD8(+) , CD3(+) CD4(+) ), B cells, natural killer (NK) cells, natural killer T cells (NK T) and monocytes by five-colour flow cytometry. Soluble E-selectin, ICAM-1, ICAM-3, platelet endothelial cell adhesion molecule (PECAM)-1, P-selectin and vascular cell adhesion molecule (VCAM)-1 were determined with a fluorescent bead-based immunoassay. The pro-migratory pattern in RRMS was verified by comparison with healthy controls and was characterized by up-regulation of LFA-1 (CD3(+) CD4(+) T cells, B cells), VLA-4 (CD3(+) CD8(+) T cells, NK cells), ICAM-1 (B cells) and ICAM-3 (NK cells). Effects of GA treatment were most pronounced after 6 months and included attenuated levels of LFA-1 (CD3(+) CD4(+) ) and VLA-4 (CD3(+) CD4(+) , CD3(+) CD8(+) , NK, NK T, monocytes). Further effects included lowering of ICAM-1 and ICAM-3 levels in almost all immune cell subsets. Soluble AM levels in RRMS did not differ from healthy controls and remained unaltered after GA treatment. The deregulated pro-migratory expression profile of cell-bound AM is altered by GA treatment. While this alteration may contribute to the beneficial action of the drug, the protracted development and unselective changes indicate more secondary immune regulatory phenomena related to these effects.read more
Citations
More filters
Journal ArticleDOI
Reassessing B cell contributions in multiple sclerosis
TL;DR: Recent advances in the field of multiple sclerosis are reviewed, and the latest evidence that B cells play an important antibody-independent role in multiple sclerosis and the prospects this holds for therapeutic intervention are discussed.
Journal ArticleDOI
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions.
TL;DR: The effects of different MS-related treatments on B cell functions that have been described up to now are summarized to find new research opportunities and contribute to the understanding of the pathogenesis of MS.
Journal ArticleDOI
B cells in multiple sclerosis.
TL;DR: An overview of the current knowledge about B cells in MS taking into account MS heterogeneity is provided, to understand how these different functions of B cells and antibodies vary among patients in order to identify which could benefit best from the different therapies.
Journal ArticleDOI
Immune regulation of multiple sclerosis by CD8+ T cells
TL;DR: Clinical relevance of these novel CD8+ T cell populations found in MS and EAE are discussed, providing insights into a potentially intriguing, novel therapeutic strategy for these diseases.
Journal ArticleDOI
Deciphering the Role of B Cells in Multiple Sclerosis—Towards Specific Targeting of Pathogenic Function
TL;DR: The current knowledge on the role of B cells, plasma cells and antibodies in MS is summarized and how approved and future treatments, first and foremost anti-CD20 antibodies, therapeutically modify these B cell components are elucidated.
References
More filters
Journal ArticleDOI
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more
TL;DR: These revisions simplify the McDonald Criteria, preserve their diagnostic sensitivity and specificity, address their applicability across populations, and may allow earlier diagnosis and more uniform and widespread use.
Journal ArticleDOI
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Chris H. Polman,Stephen C. Reingold,Gilles Edan,Massimo Filippi,Hans-Peter Hartung,Ludwig Kappos,Fred D. Lublin,Luanne M. Metz,Henry F. McFarland,Paul O'Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Brian G. Weinshenker,Jerry S. Wolinsky +13 more
TL;DR: New evidence and consensus now strengthen the role of these criteria in the multiple sclerosis diagnostic workup to demonstrate dissemination of lesions in time, to clarify the use of spinal cord lesions, and to simplify diagnosis of primary progressive disease.
Journal ArticleDOI
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.
Markus Krumbholz,Diethilde Theil,Sabine Cepok,Bernhard Hemmer,Pia Kivisäkk,Richard M. Ransohoff,Monika Hofbauer,Cinthia Farina,Tobias Derfuss,Caroline Hartle,Jia Newcombe,Reinhard Hohlfeld,Edgar Meinl +12 more
TL;DR: The strong linkage of CXCL13 to immune cells and immunoglobulin levels in CSF suggests that this is one of the factors that attract and maintain B and T cells in inflamed CNS lesions.
Journal ArticleDOI
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol,Frederik Barkhof,P Chang,Patricia K. Coyle,Douglas Jeffery,Steven R. Schwid,B Stubinski,Bernard M. J. Uitdehaag +7 more
TL;DR: There was no significant difference between interferon beta-1a and glatiramer acetate in the primary outcome, and the ability to predict clinical superiority on the basis of results from previous studies might be limited by a trial population with low disease activity.
Journal ArticleDOI
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
TL;DR: It appears that, in some individuals, in vivo administration of glatiramer acetate induces highly cross-reactive T cells that secrete Th2 cytokines, which may be useful in a variety of autoimmune disorders in which immune deviation to a Th2 type of response is desirable.
Related Papers (5)
IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases
Ping Shen,Toralf Roch,Vicky Lampropoulou,Richard A. O’Connor,Ulrik Stervbo,Ellen Hilgenberg,Stefanie Ries,Van Duc Dang,Yarúa Jaimes,Capucine Daridon,Capucine Daridon,Rui Li,Luc Jouneau,Pierre Boudinot,Siska Wilantri,Imme Sakwa,Yusei Miyazaki,Melanie D. Leech,Rhoanne C. McPherson,Stefan Wirtz,Markus F. Neurath,Kai Hoehlig,Edgar Meinl,Andreas Grützkau,Joachim R. Grün,Katharina Horn,Anja A. Kühl,Thomas Dörner,Thomas Dörner,Amit Bar-Or,Stefan H. E. Kaufmann,Stephen M. Anderton,Simon Fillatreau +32 more